Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer

Search by :

ALL Author Subject ISBN/ISSN Advanced Search

Last search:

Radium-223 and Actinium-225 α-Emitter Radiopharmaceuticals in Treatment of Metastatic Castration-Resistant Prostate Cancer

Abbasi, Akbar - Personal Name; Zakaly, Hesham M.H. - Personal Name; Mirekhtiary, Fatemeh - Personal Name;

https://mts.intechopen.com/articles/show/title/radium-223-and-actinium-225-emitter-radiopharmaceuticals-in-treatment-of-metastatic-castration-resisIn recent decades, multiple radiopharmaceutical conjugates have been tested and shown to be efficacious in treating metastasized castration-resistant prostate cancer (mCRPC). Several types of research have been published on the therapeutic use of α-emitter radiopharmaceuticals, and several authors suggested their treatment superiority. One of the suggested methods is targeted alpha therapy. In this method, alpha radiation delivers energy to cancer cells and the tumor microenvironment while minimizing toxicity to surrounding tissues. In this chapter, the alpha emitter radiopharmaceutical applications in castration-resistant prostate cancer patients were investigated. Hence, we studied the 223Ra and 225Ac α-emitter radiopharmaceuticals application method and distribution of dose throughout human body organs.https://creativecommons.org/licenses/by/3.0/en

Availability

No copy data

Detail Information

Series Title: -
Call Number: -
Publisher: : IntechOpen,., 2022-06-15.
Collation: -
Language: English
ISBN/ISSN: -
Classification: -
Content Type: -
Media Type: -
Carrier Type: -
Edition: -
Subject(s): Chapter, Part Of Book
Specific Detail Info: -
Statement of Responsibility: -

Other version/related

No other version available

File Attachment

No Data

Comments

You must be logged in to post a comment